Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Subscribe To Our Newsletter & Stay Updated
